While taste alterations during treatment with GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists often improve over time as patients adjust to treatment, several strategies can help manage these changes and maintain adequate nutrition and quality of life
The most common side effects during titration are gastrointestinal nausea, constipation, and occasionally diarrhea
Also, high treatment costs, supply constraints, and increasing competition from new obesity and diabetes therapies hinder the market
Int J Obes Relat Metab Disord 25(8):12061214 Vilsbll T, Agers H, Lauritsen T, Deacon CF, Aaboe K, Madsbad S et al (2006) The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects
Lee NC, Tang NL, Chien YH, Chen CA, Lin SJ, Chiu PC, et al